Pharvaris (NASDAQ:PHVS) Sees Strong Trading Volume – Should You Buy?

Pharvaris N.V. (NASDAQ:PHVS) shares saw an uptick in trading volume on Wednesday . 487,339 shares changed hands during trading, an increase of 60% from the previous session’s volume of 303,990 shares.The stock last traded at $34.48 and had previously closed at $34.42.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a report on Tuesday, June 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Morgan Stanley increased their price objective on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. Wells Fargo & Company assumed coverage on Pharvaris in a research note on Wednesday, July 15th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, Citizens Jmp dropped their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $50.08.

Pharvaris Stock Up 0.8%

The stock has a fifty day moving average of $33.46 and a two-hundred day moving average of $29.95. The stock has a market cap of $2.27 billion, a price-to-earnings ratio of -10.92 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.05). On average, research analysts expect that Pharvaris N.V. will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the transaction, the insider directly owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares in the company, valued at $11,185,276.83. This represents a 8.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 178,322 shares of company stock valued at $5,969,286 in the last 90 days.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System boosted its stake in shares of Pharvaris by 2.2% during the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after acquiring an additional 520 shares during the last quarter. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Quantbot Technologies LP acquired a new position in Pharvaris in the 2nd quarter valued at about $41,000. GF Fund Management CO. LTD. acquired a new position in Pharvaris in the 4th quarter valued at about $35,000. Finally, Public Employees Retirement System of Ohio lifted its holdings in Pharvaris by 20.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.